Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.7 |
mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.021 | 0.7 |
mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |